• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension.

作者信息

Xiong Ping Yu, Potus Francois, Chan Winnie, Archer Stephen L

机构信息

From the Department of Medicine and Queen's Cardiopulmonary Unit (QCPU) (P.Y.X., F.P., W.C., S.L.A.) and Biomedical and Molecular Sciences (P.Y.X.), Queen's University, Kingston, Ontario, Canada.

出版信息

Hypertension. 2018 Jan;71(1):34-55. doi: 10.1161/HYPERTENSIONAHA.117.08824. Epub 2017 Nov 20.

DOI:10.1161/HYPERTENSIONAHA.117.08824
PMID:29158355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5777609/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/851cef5af552/nihms914274f12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/9b256448e91c/nihms914274f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/8a5e6dec3801/nihms914274f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/506edc99044d/nihms914274f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/31c6e228e480/nihms914274f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/8c029bb3fe48/nihms914274f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/1b8ebec3ddb9/nihms914274f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/9a695236433c/nihms914274f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/7113767952cc/nihms914274f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/46d05d209068/nihms914274f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/55755dad2d94/nihms914274f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/c56e99b22e01/nihms914274f11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/851cef5af552/nihms914274f12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/9b256448e91c/nihms914274f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/8a5e6dec3801/nihms914274f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/506edc99044d/nihms914274f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/31c6e228e480/nihms914274f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/8c029bb3fe48/nihms914274f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/1b8ebec3ddb9/nihms914274f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/9a695236433c/nihms914274f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/7113767952cc/nihms914274f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/46d05d209068/nihms914274f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/55755dad2d94/nihms914274f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/c56e99b22e01/nihms914274f11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d290/5777609/851cef5af552/nihms914274f12.jpg

相似文献

1
Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension.世界卫生组织第2至4组肺动脉高压的模型和分子机制
Hypertension. 2018 Jan;71(1):34-55. doi: 10.1161/HYPERTENSIONAHA.117.08824. Epub 2017 Nov 20.
2
Classification of Pulmonary Hypertension.肺动脉高压的分类
Cardiol Clin. 2016 Aug;34(3):359-61. doi: 10.1016/j.ccl.2016.04.009.
3
COUNTERPOINT: Should the New Definition of PH Be the Clinical Practice Standard? No.反驳观点：肺动脉高压的新定义应成为临床实践标准吗？不应成为。
Chest. 2020 Apr;157(4):766-768. doi: 10.1016/j.chest.2019.11.018.
4
World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology.世界卫生组织第一组肺动脉高压：流行病学与病理生理学
Cardiol Clin. 2016 Aug;34(3):363-74. doi: 10.1016/j.ccl.2016.04.001.
5
Definition and classification of pulmonary hypertension.肺动脉高压的定义与分类。
Handb Exp Pharmacol. 2013;218:3-29. doi: 10.1007/978-3-642-38664-0_1.
6
The metabolic basis of pulmonary arterial hypertension.肺动脉高压的代谢基础。
Cell Metab. 2014 Apr 1;19(4):558-73. doi: 10.1016/j.cmet.2014.01.004. Epub 2014 Feb 6.
7
WHO Group 1 pulmonary arterial hypertension: current and investigative therapies.世界卫生组织 1 组肺动脉高压：现有和研究中的治疗方法。
Prog Cardiovasc Dis. 2012 Sep-Oct;55(2):89-103. doi: 10.1016/j.pcad.2012.07.002.
8
Pulmonary Hypertension and Pregnancy.肺动脉高压与妊娠。
Obstet Gynecol. 2019 Nov;134(5):974-987. doi: 10.1097/AOG.0000000000003549.
9
Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease.第5组肺动脉高压：孤儿病中的孤儿病。
Cardiol Clin. 2016 Aug;34(3):443-9. doi: 10.1016/j.ccl.2016.04.004.
10
Definition, classification, and epidemiology of pulmonary arterial hypertension.肺动脉高压的定义、分类及流行病学
Semin Respir Crit Care Med. 2009 Aug;30(4):369-75. doi: 10.1055/s-0029-1233306. Epub 2009 Jul 24.

引用本文的文献

1
The disproportionate burden of pulmonary arterial hypertension among the elderly: global, regional, and national trends from 1990 to 2021-findings from the 2021 global burden of disease study.老年人肺动脉高压的负担过重：1990年至2021年的全球、区域和国家趋势——2021年全球疾病负担研究的结果
Front Cardiovasc Med. 2025 Jul 8;12:1564785. doi: 10.3389/fcvm.2025.1564785. eCollection 2025.
2
Role of prostanoids, nitric oxide and endothelin pathways in pulmonary hypertension due to COPD.前列腺素、一氧化氮和内皮素途径在慢性阻塞性肺疾病所致肺动脉高压中的作用。
Front Med (Lausanne). 2023 Oct 10;10:1275684. doi: 10.3389/fmed.2023.1275684. eCollection 2023.
3

本文引用的文献

1
Pulmonary hypertension due to left heart disease causes intrapulmonary venous arterialization in rats.左心疾病导致的肺动脉高压可引起大鼠肺静脉动脉化。
J Thorac Cardiovasc Surg. 2017 Nov;154(5):1742-1753.e8. doi: 10.1016/j.jtcvs.2017.06.053. Epub 2017 Jul 5.
2
An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan.美国、欧洲和日本慢性血栓栓塞性肺动脉高压负担的流行病学分析。
Eur Respir Rev. 2017 Mar 29;26(143). doi: 10.1183/16000617.0121-2016. Print 2017 Mar 31.
3
The pathophysiology of chronic thromboembolic pulmonary hypertension.
Signal Transduction during Metabolic and Inflammatory Reprogramming in Pulmonary Vascular Remodeling.
代谢和炎症重编程过程中信号转导与肺血管重构
Int J Mol Sci. 2022 Feb 22;23(5):2410. doi: 10.3390/ijms23052410.
4
Histologic and proteomic remodeling of the pulmonary veins and arteries in a porcine model of chronic pulmonary venous hypertension.慢性肺静脉高压猪模型中肺静脉和肺动脉的组织学和蛋白质组重塑。
Cardiovasc Res. 2023 Mar 17;119(1):268-282. doi: 10.1093/cvr/cvac005.
5
Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence?肺动脉高压中的内皮功能障碍：原因还是结果？
Biomedicines. 2021 Jan 9;9(1):57. doi: 10.3390/biomedicines9010057.
6
Astragaloside IV blocks monocrotaline‑induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling.黄芪甲苷通过改善炎症和肺血管重构来阻断野百合碱诱导的肺动脉高压。
Int J Mol Med. 2021 Feb;47(2):595-606. doi: 10.3892/ijmm.2020.4813. Epub 2020 Dec 8.
7
Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension.发现具有高选择性且口服可用的基于苯并咪唑的磷酸二酯酶10抑制剂，其溶解度和药代动力学性质得到改善，用于治疗肺动脉高压。
Acta Pharm Sin B. 2020 Dec;10(12):2339-2347. doi: 10.1016/j.apsb.2020.04.003. Epub 2020 Apr 18.
8
Effect of EZH2 on pulmonary artery smooth muscle cell migration in pulmonary hypertension.EZH2对肺动脉高压中肺动脉平滑肌细胞迁移的影响。
Mol Med Rep. 2021 Feb;23(2). doi: 10.3892/mmr.2020.11768. Epub 2020 Dec 14.
9
The Biological Bases of Group 2 Pulmonary Hypertension.第 2 组肺动脉高压的生物学基础。
Int J Mol Sci. 2019 Nov 23;20(23):5884. doi: 10.3390/ijms20235884.
10
Ion Channels in Pulmonary Hypertension: A Therapeutic Interest?肺动脉高压中的离子通道：治疗学意义？
Int J Mol Sci. 2018 Oct 14;19(10):3162. doi: 10.3390/ijms19103162.
慢性血栓栓塞性肺动脉高压的病理生理学
Eur Respir Rev. 2017 Mar 29;26(143). doi: 10.1183/16000617.0112-2016. Print 2017 Mar 31.
4
Ischemia-induced Drp1 and Fis1-mediated mitochondrial fission and right ventricular dysfunction in pulmonary hypertension.缺血诱导的动力相关蛋白1（Drp1）和线粒体分裂因子1（Fis1）介导的线粒体分裂与肺动脉高压中的右心室功能障碍
J Mol Med (Berl). 2017 Apr;95(4):381-393. doi: 10.1007/s00109-017-1522-8. Epub 2017 Mar 6.
5
Chronic Embolic Pulmonary Hypertension Caused by Pulmonary Embolism and Vascular Endothelial Growth Factor Inhibition.肺栓塞和血管内皮生长因子抑制导致的慢性栓塞性肺动脉高压
Am J Pathol. 2017 Apr;187(4):700-712. doi: 10.1016/j.ajpath.2016.12.004. Epub 2017 Feb 7.
6
Development of a Mouse Model of Metabolic Syndrome, Pulmonary Hypertension, and Heart Failure with Preserved Ejection Fraction.代谢综合征、肺动脉高压和射血分数保留的心力衰竭小鼠模型的建立。
Am J Respir Cell Mol Biol. 2017 Apr;56(4):497-505. doi: 10.1165/rcmb.2016-0177OC.
7
Mouse Genome-Wide Association Study of Preclinical Group II Pulmonary Hypertension Identifies Epidermal Growth Factor Receptor.临床前II型肺动脉高压的小鼠全基因组关联研究确定了表皮生长因子受体。
Am J Respir Cell Mol Biol. 2017 Apr;56(4):488-496. doi: 10.1165/rcmb.2016-0176OC.
8
Novel Therapeutic Targets of Pulmonary Hypertension.肺动脉高压的新型治疗靶点
Arterioscler Thromb Vasc Biol. 2016 Dec;36(12):e97-e102. doi: 10.1161/ATVBAHA.116.308263.
9
Hypoxia induces heart regeneration in adult mice.缺氧诱导成年小鼠心脏再生。
Nature. 2017 Jan 12;541(7636):222-227. doi: 10.1038/nature20173. Epub 2016 Oct 31.
10
MicroRNA-138 and MicroRNA-25 Down-regulate Mitochondrial Calcium Uniporter, Causing the Pulmonary Arterial Hypertension Cancer Phenotype.微小RNA-138和微小RNA-25下调线粒体钙单向转运体，导致肺动脉高压癌症表型。
Am J Respir Crit Care Med. 2017 Feb 15;195(4):515-529. doi: 10.1164/rccm.201604-0814OC.